		<b>ATTY. DOCKET NO.</b> <b>4821-362-999</b> <b>(CAM 208423-999361)</b>	<b>APPLICATION NO.</b> <b>09/447,218</b>
<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		<b>APPLICANT</b> <b>Aberg et al.</b>	
<b>FILING DATE</b> <b>November 23, 1999</b>		<b>GROUP</b> Art Unit <b>1623</b>	


## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER L. E. Crane 	DATE CONSIDERED 08/02/2005
--	----------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	4821-362-999	09/447,218
	APPLICANT Aberg et al.	
FILING DATE November 23, 1999	GROUP Art Unit 1623	

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>Me</i>	CO5	5,314,697	05/1994	Kwan et al.	424	480	
<i>Me</i>	CP5	5,100,675	03/1992	Cho et al.	424	468	
<i>Me</i>	CO5	4,371,516	02/1983	Gregory et al.	424	485	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
<i>Me</i>	CR5	396,404	11/1990	EP	—	—			

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Me</i>	CS5	Clissold et al., 1989, "Loratadine A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy", <i>Drugs</i> 37:42-57
<i>DUPL.</i>	CT	"Antihistamines", 1988, <i>Chapter 16, Side Effects of Drugs Annual</i> 12:142-143 Elsevier Science Publishers
<i>Me</i>	CU5	Simons et al., 1988, "Astemizole - Induced Torsades de Pointes", <i>Lancet</i> , 624
	CV5	Temple et al., 1988, "Loratadine, an Antihistamine, Blocks antigen- and Ionophore - Induced Leukotriene Release From Human Lung In Vitro", <i>Prostaglandins</i> , 35(4):549-554
	CW5	Hilbert et al., 1987, "Pharmacokinetics and Dose Proportionality of Loratadine", <i>J. Clin. Pharmacol.</i> , 27:694-698
	CX5	Craft, 1986, "Torsade de Pointes After Astemizole Overdose", <i>British Med. J.</i> , 292: 660
	CY5	Barnett et al., 1984, "Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine", <i>Agents and Actions</i> , 14(5/6):590-597
	CZ5	Wood, 1979, "Antimotion Sickness and Antiemetic Drugs", <i>Drugs</i> , 17(17):471-479
	DA5	Cohen et al., 1972, "Meclizine and Placebo in Treating Vertigo of Vestibular Origin", <i>Arch. Neurol.</i> , 27:129-135
	DB5	Goodman and Gilman's, 1996, <i>The Pharmacological Basis of Therapeutics</i> , 9th Ed. p. 148, 588-592
	DC5	Carmeliet, 1992, "Voltage- and Time-Dependent Block of the Delayed K <sup>+</sup> Current in Cardiac Myocytes by Dofetilide", <i>J. Pharmacol. Exper. Ther.</i> , 262:809-817
	DD5	Lunde, I., 1990, "Antihistamines", <i>Side Effects of Drugs</i> , 14:135-138
	DE5	Dukes, M.N.G. et al., 1988, "Side Effects of Drugs Annual 12", Elsevier Science Publishers B.V., pp. 142-143
<i>Me</i>	DF5	Ebert, W., 1977, "Soft Elastic Gelatin Capsules: A Unique Dosage Form", <i>Pharmaceutical Technology</i> , 1:44-50
<i>Me</i>	DG5	Petrin, A., 1974, "Motion Sickness and its Treatment", <i>Schweiz. Med.</i> , 63:79-81
<i>Me</i>	DH5	Wood, C.D. et al., 1987, "Mechanisms of Antimotion Sickness Drugs", <i>Aviation, Space, and Envir. Med.</i> , pp. A262-A265

EXAMINER L. E. Crane <i>L. E. Crane</i>	DATE CONSIDERED	08/02/2005
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
<div style="border: 1px solid black; height: 40px; width: 100%;"></div>		

DUPL. Ref. "CT" is a duplicate of cite "DE."

Serial Number  
**09/447,218** Group Art Unit  
**1623** Attachment to Paper Number  
**08022005**

Notice of References Cited

APPLICANT(S)

Aberg et al.

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	<b>A</b>	<b>5,595,997 A</b>	<b>01/21/97</b>	<b>Aberg et al. (I)</b>	<b>514</b>	<b>290.000</b>	
*	<b>B</b>	<b>5,731,319 A</b>	<b>03/24/98</b>	<b>Aberg et al. (II)</b>	<b>514</b>	<b>290.000</b>	
	<b>C</b>	<b>4,282,233 A</b>	<b>08/04/81</b>	<b>Villani (I)</b>	<b>514</b>	<b>290.000</b>	
	<b>D</b>	<b>3,391,143 A</b>	<b>07/02/68</b>	<b>Kaiser et al.</b>	<b>546</b>	<b>093.000</b>	
	<b>E</b>	<b>3,326,924 A</b>	<b>06/20/67</b>	<b>Villani (II)</b>	<b>546</b>	<b>093.000</b>	

@ Cited herein for the first time: images are available for downloading on line at <www.uspto.gov>.

Foreign Patent Documents


*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	<b>L††</b>	<b>WO 85/03707 A1</b>	<b>08/29/85</b>	<b>World(WO/PCT)</b>	<b>Schering Co.</b>	<b>-----</b>	<b>-----</b>		

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	<b>R</b>	<b>Berkow et al. (I, eds.), <u>The Merck Manual of Diagnosis and Therapy, 16th Edition</u>, Merck Research Laboratories, Rahway, NJ, May, 1992, only pp. 332-334 supplied.</b>
*	<b>S†</b>	<b>Gennaro et al. (eds.), <u>Remington's Pharmaceutical Sciences, 18th Edition</u>, Mack Publishing Co., Easton, PA, 1990, only pp. 678 and 1123-1124 (from Chs. 34 &amp; 59, respectively) are supplied.</b>
*	<b>T†</b>	<b>Thomas et al. (eds.), <u>Taber's Cyclopedic Medical Dictionary, 17th Illustrated Edition</u>, F. A. Davis Company, Philadelphia, PA, 1993, only pages 2091-2092 supplied.</b>

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Supplied by applicant but not cited on a PTO-1449.

EXAMINER  
L. E. Crane   
DATE  
**07/29/05** page 1 of 6  
¥: Reference not presently available.

\*A copy of this reference is not being furnished with this office action.  
(See Manual of Patent Examining Procedure, Section 707.05(a).)

09/447,218 PTO-892 Copy for [ ] FILE  APPLICANT [ ] IFW Attachment to P. N. **08022005**

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/447,218</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number <b>08022005</b>	
<b>Notice of References Cited</b>	<b>APPLICANT(S)</b>			
	<b>Aberg et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* <b>U†</b>	<b>Bocian, R</b> , "Hay Fever (Allergic Rhinitis): Current Management Approaches," Palo Alto Medical Foundation, Spring, 2000, see < <a href="http://www.pamf.org/health/toyourhealth/hayfever/html">http://www.pamf.org/health/toyourhealth/hayfever/html</a> > .
* <b>V†</b>	<b>E. W. Monroe</b> , "Loratadine in the Treatment of Urticaria," <i>Clinical Therapeutics</i> , 19(2), 232-242 (1997).††
* <b>W</b>	<b>Knowles et al.</b> , "Astemizole and Terfenadine-Induces Cardiovascular Effects," <i>Canadian Journal of Hospital Pharmacy</i> , 45(1), 33 & 37 (Feb., 1992).††
* <b>X†</b>	<b>Isselbacher et al.</b> †† (eds.), <u>Harrison's Principles of Internal Medicine</u> , <u>Thirteenth Edition</u> , McGraw-Hill, Inc., New York, NY, 1994, only pages 402-403 supplied.
* <b>Y</b>	<b>Estelle et al.</b> ††, "The Pharmacology and Use of H <sub>1</sub> -Receptor-Antagonist Drugs," <i>The New England Journal of Medicine</i> , 330(23), 1665-1670 (June 9, 1994).
* <b>Z</b>	<b>Berkow et al.</b> †† (II, eds.), <u>The Merck Manual of Diagnosis and Therapy</u> , <u>Sixteenth Edition</u> , Merck & Co., Rahway, NJ, May, 1992, only pages 1262-1265 provided.
* <b>RA†</b>	<b>Brandes et al. (I)</b> ††, "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H <sub>1</sub> -Antihistamines: Predictive <i>in vitro</i> Correlates," <i>PubMed</i> (National Library of Medicine USA): PMID 7909571, published on line in 1994: only Abstract supplied.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Supplied by applicant but not cited on a PTO-1449.

EXAMINER L. E. Crane 	DATE <b>07/29/05</b>	page 2 of 6
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		


Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/447,218</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number <b>08022005</b>	
<b>Notice of References Cited</b>	APPLICANT(S) <b>Aberg et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* SA <sup>†</sup>	<b>E. A. Swinyard (I)</b> , "Gastrointestinal Drugs," Chapter 39 in <u>Remington's Pharmaceutical Sciences, 18th Edition</u> , Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pages 774-799 supplied.
* TA <sup>†</sup>	<b>E. A. Swinyard (II)</b> , "Histamine and Antihistamines," Chapter 59 in <u>Remington's Pharmaceutical Sciences, 18th Edition</u> , Gennaro et al. (eds.), Mack Publishing Co., Easton, PA, 1990, only pages 1123-1131 supplied.
* UA	<b>Brandes et al. (II)††</b> , "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H <sub>1</sub> -Antihistamines: Predictive <i>in vitro</i> Correlates," <i>Journal of the National Cancer Institute</i> , 86(10), 770-775 (May 18, 1994).
* VA	<b>S. L. Nightingale††</b> , "Warning Issued on Nonsedating Antihistamines Terfenadine and Astemizole," <i>Journal of the American Medical Association</i> , 268(6), 705 (Aug. 12, 1992).
* WA <sup>†</sup>	<b>Berthon et al.††</b> , "In Vitro Inhibition, by Loratadine and Descarbethoxy-loratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in Rat Basophilic Leukemia Cells (RBL-2H3)," <i>Biochemical Pharmacology</i> , 47(5), 789-794 (1994).
* XA	<b>J. F. Wiley II, et al.††</b> , "Cardiotoxic Effects of Astemizole Overdose in Children," <i>Journal of Pediatrics</i> , 120(5), 799-802 (May, 1992).

<sup>†</sup> Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

<sup>††</sup> Supplied by applicant but not cited on a PTO-1449.


EXAMINER L. E. Crane 	DATE <b>07/29/05</b>	page 3 of 6
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/447,218</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number <b>08022005</b>	
<b>Notice of References Cited</b>	APPLICANT(S) <b>Aberg et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* YA†	A. Van Peer et al.††, "Ketoconazole Inhibits Loratadine Metabolism in Man," <i>European Journal of Allergy &amp; Clinical Immunology</i> , 48(Suppl. 16), 34, 1993: Derwent Abstract Accessio No.: 93-55671; only abstract supplied.
* ZA†	C. I. Ezeamuzie et al.††, "Effect of Histamine H <sub>2</sub> -Receptor Antagonists on Acute Inflammatory of the Rat Paw Oedema," <i>J. Pharm. Pharmacol.</i> , 41, 261-265 (1989).
* RB†	K. Kyuki et al.††, "Topical Anti-Inflammatory Activity of Dexamethasone 17-Valerate," <i>Nippon Yakurigaku Zasshi</i> , 77(1), 73-85 (January, 1981); Pub Med Abstract/Translation from Japanese, PMID 7262708; only Abstract supplied.
* SB†	S. Kawaguchi et al.††, "Nasal Mast Cell in Experimentally Induced Allergic Rhinitis in Guinea-Pigs," <i>Clinical and Experimental Allergy</i> , 24, 238-244 (1994).
* TB†	T. Abe et al.††, "Antiallergic Effects of ZCR-2060: Effect on Allergic Cutaneous Reactions and Rhinitis Models in Mice and Rats," <i>Japanese Journal of Pharmacology</i> , 66, 95-103 (1994).
* UB†	A. G. Gilman et al. (I, eds.)††, <u>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition</u> , Pergamon Press, New York, NY, 1990, only pages 7, 197-199 and 582-588 supplied.
* VB†	A. G. Gilman et al. (II, eds.)††, <u>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition</u> , Pergamon Press, New York, NY, 1996, only page 588 supplied.

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. E. Crane 	DATE <b>07/29/05</b>	page 4 of 6
¥: Reference not presently available.		
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		

Notice of References Cited

APPLICANT(S)

Aberg et al.

†† Supplied by applicant but not cited on a PTO-1449.

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

* WB†	A. P. Good et al.††, "Loratadine and Ventricular Tachycardia," <i>Journal of Cardiology</i> , 74(15), 207 (1994).
* XB†	K. Nyman et al.††, "Serious Side Effects of the Antiallergic Loratadine - Warning Against Long-Term Use of Non-Prescription Preparation," <i>Lakartidningen</i> , 99(25), 2281 (1992); only English translation provided.
* YB	R. W. Brimblecomb et al.††, "The Pharmacology of Burimamide and Metiamide, Two Histamine H <sub>2</sub> Receptor Antagonists," <i>Federation Proceedings</i> , 35(8), 1931-1934 (June, 1976).
* ZB†	N. Takahashi et al.††, "Allergic Rhinitis Model with Brown Norway Rat and Evaluation of Antiallergic Drugs," <i>Journal Pharmacobio-Dyn.</i> , 13, 414-420 (1990).
* RC†	<u>Merck Index</u> , 12th Edition††, Merck & Co., Rahway, NJ, 1990, only pages 132, 892, 5611 and 9307 supplied.
* SC†	H. G. Mandel ††, "Pathways of Drug Biotransformation: Biochemical Conjugates," Chapter 10 in <u>Fundamentals of Drug Metabolism and Drug Disposition</u> , Williams & Wilkins, Baltimore, MD, 1971, only pages 149-151 supplied.
* TC†	A. Goth ††, <u>Medical Pharmacology</u> , 9th Edition, [], 1978, only pages 18, 19 and 33 supplied. **
* UC†	P. L. Munson et al.†, <u>Principles of Pharmacology</u> , [], 1996, only pages 458-459, 770 and 812 supplied. **

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Supplied by applicant but not cited on a PTO-1449.

\*\* Incomplete bibliographic information; missing publisher's name and location of the publisher.

EXAMINER

L. E. Crane

DATE

07/29/05

page 5 of 6

¥: Reference not presently available.

\*A copy of this reference is not being furnished with this office action.  
(See Manual of Patent Examining Procedure, Section 707.05(a).)


Form PTO-892 U.S. Department of Commerce	Serial Number <b>09/447,218</b>	Group Art Unit <b>1623</b>	Attachment to Paper Number <b>08022005</b>	
<b>Notice of References Cited</b>	<b>APPLICANT(S)</b>			
	<b>Aberg et al.</b>			

**Other References (Including Author, Title, Date, Pertinent Pages, etc.)**

* VC <sup>†</sup>	R. L. Woolsey et al. <sup>††</sup> , "Effects of Astemizole and Its Metabolites on Cardiac Repolarization," Georgetown University Document No. AST-2, Georgetown University, Washington, D.C., 1995; see also Sepracor Document No. 110-408.
* WC <sup>†</sup>	R. Arky et al. (eds.), <u>Physician's Desk Reference, 1994 Edition</u> , <sup>††</sup> Medical Economics Data Production Company, Montvale, NJ, only pages 1087-1090 supplied.
* XC <sup>†</sup>	A. G. Gilman et al. (III, eds.) <sup>††</sup> , <u>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition</u> , Pergamon Press, New York, NY, 1996, only page 590 supplied.
* YC	EPO Oral Proceeding <sup>††</sup> , written record of "Refusal of an EP Patent Application for EP Application No. 95 943 722.9-2112, 08 September 2000, see entire document.

<sup>†</sup> Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

<sup>††</sup> Supplied by applicant but not cited on a PTO-1449.

EXAMINER L. E. Crane 	DATE <b>07/29/05</b>	page 6 of 6 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		